Oppenheimer Remains Bullish on Merrimack Pharma (MACK) Following Recent Phase II Amendment
Tweet Send to a Friend
Oppenheimer Reiterated an Outperform rating and $15.00 price target on Merrimack Pharmaceuticals (NASDAQ: MACK) following the company's recently filed amendment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
